

1 **Title:** *Plasmodium falciparum* multidrug resistance 1 gene polymorphisms associated with
2 outcomes after antimalarial treatment

3 **Running title:** *Pfmdr1* and malaria outcomes

4 Veronika R. Laird^{1,2,3}, Mateusz M. Plucinski², Meera Venkatesan⁴, Kelsey A. Rondini^{2,5},
5 Milijaona Randrianarivelosoa^{6,7}, Mauricette N. Andriamananjara⁸, Hawela Moonga⁹, Deus S.
6 Ishengoma¹⁰, Arlindo Chidimatembue¹¹, Pedro Rafael Dimbu¹², Adicatou-Lai Adeothy¹³,
7 Abdoul Habib Beavogui¹⁴, Simon Kariuki¹⁵, Sam L. Nsohya¹⁶, Aline Uwimana¹⁷, Gauthier
8 Mesia Kahunu^{18,19}, Ashenafi Assefa²⁰, Ousmane A. Koita²¹, Naomi W. Lucchi^{22,23}, Samaly S.
9 Svigel Souza²³, Zhiyong Zhou²³, Leah F. Moriarty², Eric S. Halsey²

10

11 **Article word count (Introduction through Discussion):** 3,488

12 **Corresponding author:**

13 Veronika R. Laird

14 2006 E Lombard

15 Baltimore, MD

16 21231

17 USA

18

19 veronika.laird97@gmail.com

20

21 Alternate corresponding author:

22 Eric Halsey

23 1600 Clifton Road

24 Mail Stop: H16-4

25 Atlanta, GA 30329

26 USA

27

28 **Affiliations:**

29 ¹Department of Epidemiology, Emory University, Atlanta, GA, USA.

30 ²US President's Malaria Initiative, Malaria Branch, Division of Parasitic Diseases and Malaria,
31 Centers for Disease Control and Prevention, Atlanta, GA, USA

32 ³Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee, United States

33 ⁴US President's Malaria Initiative, United States Agency for International Development,
34 Washington, DC, USA

35 ⁵Booz Allen Hamilton, Atlanta, GA, USA

36 ⁶Institut Pasteur de Madagascar, Antananarivo, Madagascar

37 ⁷Faculté des Sciences, Université de Toliara, Toliara, Madagascar

38 ⁸Direction de La Démographie et des Statistiques Sociales, Institut National de La Statistique,
39 Antananarivo, Madagascar

40 ⁹National Malaria Elimination Centre, Zambia Ministry of Health, Lusaka, Zambia

41 ¹⁰National Institute for Medical Research, Dar es Salaam, Tanzania

42 ¹¹Centro de Investigação em Saúde de Manhiça (CISM), Maputo, Mozambique

43 ¹²National Malaria Control Program, Ministry of Health, Luanda, Angola

44 ¹³National Malaria Control Program, Ministry of Health, Porto-Novo, Benin

45 ¹⁴Centre National de Formation et de Recherche en Santé Rurale de Maferinyah, Forecariah,
46 Guinea

47 ¹⁵Kenya Medical Research Institute (KEMRI)-Centre for Global Health Research, Kisumu,
48 Kenya

49 ¹⁶Infectious Diseases Research Collaboration (IDRC), Kampala, Uganda

50 ¹⁷Malaria and Other Parasitic Diseases Division, Rwanda Biomedical Centre (RBC), Kigali,
51 Rwanda

52 ¹⁸Unit of Clinical Pharmacology and Pharmacovigilance University of Kinshasa, Kinshasa,
53 Democratic Republic of the Congo

54 ¹⁹Department of Pharmacology and Therapeutics, University of Kinshasa, Kinshasa, Democratic
55 Republic of the Congo

56 ²⁰Ethiopian Public Health Institute, Arbegnoch Street, Addis Ababa, Ethiopia

57 ²¹Mali-Tulane Tropical Medicine Research Center, Faculty of Medicine, Pharmacy, and
58 Dentistry, University of Bamako, Bamako, Mali

59 ²²U.S. President's Malaria Initiative, US Centers for Disease Control and Prevention, Kigali,
60 Rwanda

61 ²³Malaria Laboratory Research & Development Team, Malaria Branch, U.S. Centers for Disease
62 Control and Prevention, Atlanta, GA, USA

63

64 **Author contributions**

65 Developed the study idea: VL, MP, MV, EH

66 Collected the data: MR, MA, HW, DI, AC, PD, AA, AB, SK, SN, AU, GK, AA, OK, NL, SS,
67 ZZ

68 Analyzed the data: VL, MP, KR, LM, EH

69 Wrote the manuscript: VL, MP, EH

70 Approved the manuscript: All

71

72 **Article summary:**

73 This study suggests that: 1) patients given AL infected with parasites carrying N86 were
74 statistically more likely to experience a recurrent infection; 2) patients given ASAQ infected
75 with parasites carrying 86Y were statistically more likely to experience a recurrent infection.

76 **Abstract word count: 200**

77

78 **Background.** *Plasmodium falciparum* multidrug resistance transporter 1 (*Pfmdr1*) gene
79 mutations are associated with altered response to artemisinin-based combination therapies
80 (ACTs), particularly those containing the partner drugs lumefantrine and amodiaquine (i.e.,
81 artemether-lumefantrine [AL] and artesunate-amodiaquine [ASAQ]). Past studies of *Pfmdr1*
82 single nucleotide polymorphisms (SNPs) at codons 86, 184, and 1246 have shown different
83 responses to AL and ASAQ.

84 **Methods.** To determine whether infection with parasites carrying specific *Pfmdr1* SNPs
85 leads to increased risk of recurrent parasitemia (recrudescent or new infection), data from 4,129
86 samples from 16 therapeutic efficacy studies from 13 African countries between 2013–2019
87 were analyzed.

88 **Results.** Patients treated with AL and infected with parasites carrying *Pfmdr1* N86 were
89 at greater risk of treatment failure than those whose parasites carried 86Y. After treatment with
90 ASAQ, individuals infected with parasites that carried *Pfmdr1* 86Y were more likely to
91 experience a recurrent infection.

92 **Conclusions.** Our results support prior studies that suggested: 1) patients given AL and
93 infected with parasites carrying N86 were more likely to experience a recurrent infection; 2)
94 patients given ASAQ and infected with parasites carrying 86Y were more likely to experience
95 recurrent infection. These findings suggest that ACT and *Pfmdr1* genotype may influence
96 outcome after *P. falciparum* infection.

97

98 **Keywords.** malaria, *Plasmodium falciparum*, Africa, antimalarials, drug resistance

99 **Introduction**

100 The emergence of *Plasmodium falciparum* resistance to antimalarials poses a challenge
101 to global malaria control efforts. World Health Organization (WHO) Guidelines for Malaria
102 recommend the use of artemisinin-based combination therapy (ACT) to treat uncomplicated *P.*
103 *falciparum* infection (1). Three ACTs used in Africa are artemether-lumefantrine (AL),
104 artesunate-amodiaquine (ASAQ), and dihydroartemisinin-piperaquine (DP) (2). Although
105 polymerase chain reaction (PCR)-adjusted efficacy for each ACT remains high throughout most
106 regions (3), suboptimal ACT efficacy has been reported in Asia (4) and Africa (5–7).

107 Although ACT resistance has not been demonstrated with any particular *Plasmodium*
108 *falciparum* multidrug resistance transporter 1 single nucleotide polymorphism (SNP) or
109 haplotype, certain SNPs may affect response after treatment with ACTs containing lumefantrine
110 or amodiaquine (8,9). Five unique *Pfmdr1* SNPs, with amino acid changes in codons 86, 184,
111 1034, 1042, and 1246, have been found in various regions of the world (10). N86, 184F, and
112 D1246 SNPs have been found in post-treatment samples of patients who experienced a recurrent
113 infection after AL treatment (9,11,12). Conversely, studies of SNPs in *Pfmdr1* have suggested
114 that the 86Y and 1246Y mutations may be associated with decreased response to amodiaquine
115 and ASAQ (9,13). Several *in vivo* studies in sub-Saharan Africa have found evidence of selection
116 for particular *Pfmdr1* SNPs at codons 86, 184, and 1246 after treatment with AL (9,14,15).
117 *Pfmdr1* SNPs present post-treatment in new infections are also important to understand because
118 they may impact the post-treatment prophylactic effect of the partner drug (16). Increased copy
119 number of *Pfmdr1* due to gene duplications has also been associated with reduced susceptibility
120 to lumefantrine (10,17).

121 Sample sizes in individual therapeutic efficacy studies (TESs) are typically too small
122 to statistically power an assessment of the association between parasite genotypes and treatment

123 outcomes (i.e., adequate clinical and parasitological response, recrudescent infection, and new
124 infection). As part of the US President’s Malaria Initiative (PMI), the Centers for Disease
125 Control and Prevention (CDC) and the US Agency for International Development provide
126 support to countries in Africa to perform TESs, including molecular characterization of
127 antimalarial-resistance markers, through the Partnership for Antimalarial Resistance Monitoring
128 in Africa (PARMA) network (18). Established in 2015, this endeavor involves laboratory
129 scientists from endemic countries coming to CDC (Atlanta, Georgia, USA) or, starting in 2022,
130 to a partner lab in Africa to receive advanced laboratory training and perform molecular testing
131 for antimalarial-resistance mutations (18). To examine the association between parasite
132 genotypes and treatment outcomes, *in vivo* antimalarial efficacy and *P. falciparum* molecular
133 marker data from samples analyzed and collected from 16 TESs conducted in 13 countries in
134 Africa were used. Understanding this association is important for detecting changes in long-term
135 trends of *Pfmdr1* SNP prevalence in parasite populations as indicators of changing parasite
136 susceptibility to ACT partner drugs, lumefantrine or amodiaquine. This study had two main
137 objectives to untangle the relationship between parasite *Pfmdr1*-genotypes and treatment
138 outcomes: 1) To assess whether patients infected with parasites carrying specific *Pfmdr1* SNPs
139 have increased risk of recurrent infection; 2) To investigate preferential selection of specific
140 *Pfmdr1* SNPs by ACT type.

141 **Methods**

142 *Selection and inclusion of data*

143 Data for this pooled analysis were compiled from 16 individual TESs from 40 sites across
144 13 sub-Saharan African countries between 2013–2019 (Figure 1, Supplementary Table 1, and
145 Supplementary Table 2). The studies were all funded by PMI.

146 Patients with symptomatic, parasitologically-confirmed uncomplicated *P. falciparum*
147 symptomatic infection who presented to health facilities and met standard WHO inclusion
148 criteria were enrolled (Supplementary Table 2) (24). Patients were administered either AL,
149 ASAQ, or DP. After follow-up was complete, parasite genetic sequencing of *Pfmdr1* was
150 conducted at the CDC Malaria Branch Laboratory in Atlanta, USA. This was conducted as part
151 of a training program through PARMA (18). Eleven TES results have been published alongside
152 molecular results, three TES efficacy results were published separately from the molecular
153 surveillance results, and two results are contained in unpublished country reports (Benin and
154 Zambia) (Supplementary Table 2).

155

156 *Genotyping of Pfmdr1 SNPs and result calling*

157 Patients were considered to have a recurrent infection if their sample was found by
158 microscopy to contain asexual forms of *P. falciparum* starting on day 4 after ACT treatment until
159 the end of the follow-up period (28, 28, and 42 days for AL, ASAQ, and DP, respectively). For
160 study participants with recurrent infection, the recurrent infection sample and its corresponding
161 pre-treatment sample were genotyped to determine whether the recurrent infection was a
162 recrudescence or new infection. This was done using either seven neutral microsatellite
163 markers (*TA1*, *Poly-α*, *PfPK2*, *TA109*, *TA2490*, *C2M34*, and *C3M69*) over six chromosomes
164 (20,21) or using the fragment length polymorphism of genes *merozoite surface protein 1*,
165 *merozoite surface protein 2*, and *glutamate-rich protein* (*mSP1*, *mSP2*, and *glurp*) (22).

166 *Pfmdr1* codons 86, 184, 1034, 1042, and 1246 were sequenced in parasites collected from
167 enrolled patients who experienced a recurrent infection from each TES and the SNP at each
168 codon was recorded. Each TES sequenced *Pfmdr1* codons 86, 184, 1034, 1042, and 1246 for

169 typically 10% of enrolled patients who experienced an adequate clinical and parasitological
170 response except for the Angola (2013, 2017, 2019), Democratic Republic of the Congo, and
171 Uganda TESSs. Sanger sequencing was used to determine the genotype of the five *Pfmdr1* SNPs
172 in pre-treatment and recurrent infections samples for each study except the 2019 Angola TES,
173 which utilized next generation sequencing. For each SNP, samples were classified as having
174 either a single or mixed infection (mixed genotypes) depending on whether heterozygous SNPs
175 (double peaks representing mixed infections) were identified using the heterozygous call plug-in
176 tool in Geneious software package (Biomatters, Inc., San Francisco, CA) with a minor allele
177 threshold of at least 30%. Mixed infections were recorded in each study except for Tanzania. For
178 samples with mixed infections and SNP variations at codons 86, 184 and 1246, each possible
179 haplotype constructed from the observed SNPs was reported for *Pfmdr1*(23). *Pfmdr1* codons
180 1034 and 1042 were not included in the statistical analysis because the vast majority exclusively
181 carried the wild-type SNP.

182 Mixed infections at the codons of interest included N and Y at codon 86 (N/Y), Y and F
183 at codon 184 (Y/F), and D and Y at codon 1246 (D/Y). For the odds ratio analysis, mixed
184 infections were reclassified to one SNP per codon for each treatment arm. This baseline SNP
185 served as the exposure. For patients treated with AL, mixed infections at codon 86 were
186 reclassified as N86; at codon 184 as 184F; and at codon 1246 as D1246. This is because previous
187 studies have found N86, 184F, and D1246 to predominate in patients after AL treatment
188 (9,11,12). For patients treated with ASAQ or DP, mixed infections at codon 86 were reclassified
189 as 86Y; at codon 184 as Y184; and at codon 1246 as 1246Y. This is because previous studies
190 have found 86Y, Y184, and 1246Y to predominate in patients after treatment with amodiaquine
191 (11,13,24). Patients with mixed infections following treatment with DP were classified similarly

192 to those treated with ASAQ because piperaquine has been shown to exert selective pressure on
193 *Pfmdr1* in the same direction as amodiaquine (25,26). We examined all recurrent infections,
194 which included recrudescence and new infections, rather than examining solely recrudescence
195 infections. New infections were included in this analysis because the *Pfmdr1* SNPs present post-
196 treatment could make the parasite less susceptible to ACTs since the parasite was able to re-
197 infect individuals soon after treatment, negating the potential post-treatment prophylactic effect
198 of the partner drug.

199 *Statistical analysis*

200 All statistical analyses were conducted using R version 4.2.2 (R Foundation for Statistical
201 Computing, Vienna, Austria). Multiple sensitivity analyses using only recrudescence infections
202 were done to assess potential bias that could occur when analyzing new infections and
203 recrudescence infections together. The first sensitivity analysis investigated the association
204 between those treated with AL that experienced a recrudescence infection and *Pfmdr1* codons 86
205 and 184. This could not be done with *Pfmdr1* codon 1246 due to small sample size. A second
206 sensitivity analysis investigated the association between those treated with ASAQ who
207 experienced a recrudescence infection and *Pfmdr1* codon 184. Due to the limited sample size, a
208 sensitivity analysis for those treated with ASAQ who experienced a recrudescence and *Pfmdr1*
209 codon 86 and 1246 could not be conducted. Similarly, a sensitivity analysis was not performed
210 for those treated with DP since so few recrudescence infections occurred in those receiving this
211 ACT. After this, to determine whether patients infected with parasites carrying specific *Pfmdr1*
212 SNPs were at increased risk of recurrent (recrudescence or new) infections, the Mantel-Haenszel
213 (MH) method was used to create forest plots. To ensure there was not significant heterogeneity
214 among studies, a Cochran's Q test was used ($p > 0.05$). Since no statistically significant

215 heterogeneity was found among studies, the common effect odds ratio was reported (27). Each
216 forest plot was created to display the common effect odds ratio by treatment arm for each
217 country-specific study and the pooled MH odds ratio by treatment arm when the data from all
218 studies were compiled.

219 The common effect odds ratio represented the odds of a specific SNP in recurrent
220 infections (in day of failure samples from those with recrudescence or new infections) compared
221 to the odds of that same SNP in successfully treated infections (in pre-treatment samples from
222 those who experienced an adequate clinical or parasitological response or in pre-treatment
223 samples who initially cleared their infection but would later acquire a new infection). For the
224 category of samples from successfully treated patients, we included: 1) pre-treatment samples
225 from those with an adequate clinical and parasitological response; and 2) pre-treatment samples
226 from those who would go on to be infected with a different parasite (i.e., new infection). This is
227 because the pre-treatment infection was successfully cleared. For the category of unsuccessfully
228 treated patients, we included: 1) the post-treatment recrudescence samples; and 2) the post-
229 treatment samples from those patients who were newly infected (because the patient experienced
230 an infection while the long-acting partner drug was still circulating). Conditional logistic
231 regression was used to investigate the relationship between all the two-codon (e.g., 86Y and
232 Y184) and three-codon haplotype (e.g., N86, 184F, and D1246) combinations with the
233 occurrence of recurrent infections.

234 In patients who experienced either a recrudescence or new infection during the follow-up
235 period, the *Pfmdr1* SNPs of the pre-treatment and recurrent sample were compared for each of
236 these outcomes using McNemar's test to examine selection. SNPs from pre-treatment samples
237 were compared to their corresponding recurrent infection SNP to confirm that differences

238 represented selection rather than original differences in SNP frequencies among the population
239 (9).

240 **Results**

241 *Baseline prevalence of genetic markers associated with resistance*

242 The baseline prevalence of SNPs was determined using all successfully sequenced pre-
243 treatment samples. Pre-treatment SNPs at position 86 were analyzed for 2,999 samples, at
244 position 184 for 3,050 samples, at position 1034 for 3,006 samples, at position 1042 for 3,006
245 samples, and at position 1246 for 3,027 samples (Table 1).

246 The prevalence of *Pfmdr1* SNPs varied by country (Table 1). The *Pfmdr1* N86 SNP was
247 found in the majority of samples from every country, with the prevalence ranging from 53–
248 100%. Samples from Ethiopia, Kenya, Mozambique, Tanzania, Uganda, and Zambia almost
249 exclusively carried the *Pfmdr1* N86 SNP. *Pfmdr1* 184 had the most variation, with the
250 prevalence of 184Y SNP ranging from 23–66%. Almost all samples carried parasites with the
251 *Pfmdr1* S1034 and *Pfmdr1* N1042 wild-type alleles except for two participants from the
252 Democratic Republic of the Congo, who carried parasites with both *Pfmdr1* 1034C and *Pfmdr1*
253 1042D. *Pfmdr1* D1246 SNP was found in 81–100% of the samples from most countries, with
254 the Democratic Republic of the Congo having *Pfmdr1* D1246 in 81% of samples.

255 *Parasite single nucleotide polymorphisms as risk factors for recurrent infection*

256 For patients treated with AL, the odds ratio between those with wild-type N86 in
257 recurrent infections and those with wild-type N86 in infections that were successfully cleared
258 was 5.22 (95% CI 2.69, 10.13) (Figure 2, panel a). For those treated with ASAQ, the odds of the
259 86Y SNP in recurrent infections was 2.72 (95% CI 1.28, 5.79) times higher than the odds of the
260 same SNP in infections that were successfully cleared (Figure 2, panel b). There was no

261 association detected between *Pfmdr1* codon 86 and recurrent infection for those treated with DP
262 (Figure 2, panel c). Similarly, there was no association between *Pfmdr1* codons 184 or 1246 and
263 recurrent infection in those treated with AL, ASAQ, or DP (Figures 3 and 4). When examining
264 recrudescence infections alone (and not combined with new infections), the results of the
265 sensitivity analysis were not statistically significant, although the odds ratios were either in the
266 same direction as the aforementioned results or no effect was found (Supplementary Figures 1
267 and 2).

268 Country-specific odds ratios could not be generated for several countries for some
269 treatment arms and SNPs. For example, patients who received AL in the Uganda TES only had
270 parasites carrying the N86 SNP and none carrying the 86Y SNP following reclassification of
271 mixed infections. Thus, the country-specific odds ratio was undefined and could not contribute to
272 the overall, pooled MH odds ratio.

273 *Post-treatment selection of genetic markers associated with reduced susceptibility*

274 To examine changes in the genetic markers of parasites after drug treatment during the
275 period of follow-up, we compared the prevalence of *Pfmdr1* SNPs in paired isolates from the
276 initial and the recurrent parasites (Table 2). Statistically significant selection of *Pfmdr1* N86
277 occurred in new infections as well as recurrent infections (recrudescence infections plus new
278 infections) after treatment with AL. There was no statistically significant selection of *Pfmdr1*
279 SNPs at codons 184 or 1246 after AL treatment and no statistically significant selection of SNPs
280 at *Pfmdr1* codons 86, 184, or 1246 after ASAQ or DP treatment.

281 *Parasite haplotypes as a risk factor for recurrent infection*

282 Recurrent infections, which included recrudescence and new infections, were pooled to
283 assess the relationship between *Pfmdr1* haplotype and recurrent infections. Only one haplotype,

284 N86/184F, was found to be associated with recurrent infection. The odds of N86/184F among
285 individuals with recurrent infection after AL treatment (post-treatment) was 6.36 (95% CI 1.39,
286 29.19) times higher than the odds of the same haplotype among those that successfully cleared
287 the infection (pre-treatment). The combined effect of carrying N86/184F had a greater measure
288 of association (OR: 6.36, 95% CI: 1.39, 29.19) than recurrent parasites only carrying N86 (OR:
289 5.22, 95% CI: 2.69, 10.13). There was no statistically significant selection of *Pfmdr1* haplotypes
290 at codons 184 or 1246 after AL treatment and no statistically significant selection of haplotypes
291 at *Pfmdr1* codons 86, 184, or 1246 after ASAQ or DP treatment.

292

293 **Discussion**

294

295 This pooled analysis of data from 16 efficacy studies suggests that SNPs in *Pfmdr1* codon
296 86 influence recurrent infection after AL and ASAQ treatment. Individuals infected with
297 parasites that carried the *Pfmdr1* N86 SNP were statistically more likely to experience a
298 recurrent infection after treatment with AL. This finding is consistent with a previous study
299 which found that patients treated with AL and infected with parasites carrying the *Pfmdr1* N86
300 allele were at statistically greater risk of treatment failure than those whose parasites carried
301 86Y(9). This increased risk of recurrent infection, in addition to significant selection of *Pfmdr1*
302 N86 by AL, could be an indicator of decreased susceptibility to the partner drug, lumefantrine.

303 For our haplotype analysis, patients given AL and infected with parasites carrying
304 *Pfmdr1* N86/184F were statistically more likely to cause a new infection. This finding is similar
305 to a study which found that after AL treatment, individuals carrying *Pfmdr1* N86/184F/D1246
306 were able to re-infect with lumefantrine blood concentrations 15-fold higher than those with the
307 86Y/Y184/1246Y haplotype (8). Another study discovered that individuals with *Pfmdr1*

308 N86/D1246 experienced a new infection earlier after AL treatment (9). These findings suggest
309 that monitoring for decreasing post-treatment durations until a new infection has occurred or
310 surveilling for the prevalence of certain post-treatment *Pfmdr1* haplotypes may also provide
311 indications of decreased susceptibility to lumefantrine.

312 After treatment with ASAQ, individuals infected with parasites that carried the *Pfmdr1*
313 86Y SNP were statistically more likely to cause a recurrent infection, shown in this study. Like
314 our results from those treated with AL, a high prevalence of *Pfmdr1* 86Y SNP may be an early
315 warning signal of resistance to the partner drug, amodiaquine, but this association requires
316 further investigation because prior studies are collectively inconclusive. An *in vitro* analysis
317 from Southern Sudan found a significant association between failure after amodiaquine treatment
318 and the combined presence of *Pfmdr1* 86Y and *Pfcr1* 76T but no association with *Pfmdr1* 86Y
319 alone (28). However, an *in vivo* study from Burkina Faso found a significant association between
320 *Pfmdr1* 86Y and treatment failures after amodiaquine treatment and another *in vivo* study from
321 Burkina Faso showed significant selection of *Pfmdr1* 86Y after treatment with ASAQ (24,29).
322 Additionally, a meta-analysis revealed that the risk of therapeutic failure was greater for
323 participants who carried *Pfmdr1* 86Y and were treated with amodiaquine monotherapy (30). Our
324 results align with the findings from Burkina Faso and the meta-analysis. Close monitoring of the
325 prevalence of *Pfmdr1* codon 86 before and after treatment with amodiaquine monotherapy or
326 ASAQ could be used to indicate potential partner-drug resistance to amodiaquine.

327 Unlike previous studies, this analysis did not find statistically significant selection of
328 *Pfmdr1* SNPs by ASAQ (9,11,31–34). There were no significant findings between the use of DP
329 and treatment outcomes or selection of *Pfmdr1* SNPs by DP. While this lack of association has
330 been found before, there has also been evidence of piperazine exerting a selective pressure on

331 *Pfmdr1* genes similar to amodiaquine (25,26). However, there was clear evidence of significant
332 selection of *Pfmdr1* N86 by AL in those who experienced either a recurrent infection (i.e.,
333 recrudescence or new infection) or a new infection alone in this study. This result aligns with prior
334 studies that found selection of particular *Pfmdr1* SNPs among parasite populations after
335 treatment with AL (8,9,12,15,17,35–40). Additionally, the significant selection of *Pfmdr1* N86
336 by AL is consistent with prior molecular studies that identified changes in the parasite population
337 prevalence of *Pfmdr1* SNPs after the introduction or greater use of lumefantrine (14,15,34–
338 37,41,42).

339 Although SNPs at *Pfmdr1* codon 86 were associated with recurrent infections (i.e.,
340 recrudescence or new infections), they were not associated solely with recrudescence infections in
341 those treated with AL or ASAQ, an association shown in a prior study (9). The small number of
342 recrudescence infections, a limitation of this study even with pooled data across 16 TES, may have
343 prevented this analysis from finding significant results. A similar limitation was the smaller
344 number of patients receiving ASAQ, which may have contributed to the lack of evidence of
345 selection for *Pfmdr1* 86Y by ASAQ, a selection other studies have demonstrated [16, 23, 49–51].
346 Another limitation was that information on the number of *Pfmdr1* copies was not available for
347 the majority of studies included in this analysis but has been previously found as a predictor of
348 treatment failure after AL treatment (10,17). Additionally, most of the efficacy studies enrolled
349 patients under 6 years old. Therefore, our data may not be applicable to adult populations. Lastly,
350 efficacy studies are not countrywide but occur in just a few sites, which may not be
351 representative of an entire country's parasite population. Despite its limitations, our study
352 possessed many strengths, including the large number of samples from numerous countries that
353 were sequenced at the same laboratory using the same methodology.

354 Two patients from the Democratic Republic of the Congo carried parasites bearing the
355 *Pfmdr1* haplotype commonly found in South America, *Pfmdr1* 1034C, 1042D, and 1246Y,
356 which has been associated with increased sensitivity to artemisinin (39,43,44). However, in our
357 study, the participants experienced a new infection after treatment with DP. Because detailed
358 travel histories were not available for these patients, it is unknown whether they acquired their
359 infections locally or abroad.

360 Changes in the prevalence of *Pfmdr1* SNPs over multiple TESs can be a subtle sign of
361 selection of parasite populations by AL or ASAQ. Decreasing efficacy of lumefantrine,
362 amodiaquine, or other partner drugs leaves the artemisinin component of an ACT vulnerable to
363 new selective pressures. Modeling demonstrates that partner drug resistant *Pfmdr1* genotypes
364 may lead to establishment of artemisinin resistance (45). This phenomenon may already be
365 occurring in Africa. Rwanda and Uganda, two countries reporting *K13* mutations associated with
366 artemisinin resistance, use AL as their first-line ACT and had a predominance of the *Pfmdr1* N86
367 genotype in our study (7,46,47). Previous studies have shown that ASAQ and AL exert opposing
368 selecting pressures on *Pfmdr1* 86 (9). Depending on the prevalence of *Pfmdr1* polymorphisms,
369 the opposing selection by the partner drugs could better inform which ACT national malaria
370 control programs could choose as a first-line therapy to delay resistance to both drugs. New
371 strategies, such as multiple first-line therapies or dosing lumefantrine and amodiaquine together
372 as part of a triple therapy, may overcome the negative effects of a particular *Pfmdr1* SNPs
373 associated with decreased susceptibility to partner drugs, although that remains to be proven (48–
374 50). Monitoring prevalence of *Pfmdr1* codons, such as N86Y, may indicate a parasite genetic
375 background conferring reduced susceptibility to a particular antimalarial.

376

377 **Acknowledgements**

378 The authors would like to acknowledge Venkatachalam Udhayakumar for his suggestions on the
379 manuscript and for supporting the laboratory genotyping trainings vital to this multi-country
380 endeavor. All authors have no conflicts of interest.

381

382 **Funding**

383 Funding for this assessment was obtained from the United States President's Malaria Initiative
384 (PMI) via the Office of Health, Infectious Diseases, and Nutrition, Bureau for Global Health, US
385 Agency for International Development. Staff from PMI were involved in the development of the
386 protocol, survey tools, survey implementation, data analysis, and manuscript preparation.

387 **Disclaimer**

388 The opinions expressed herein are those of the author(s) and do not necessarily reflect the views
389 of any collaborating institute including the Centers for Disease Control and Prevention or the US
390 Agency for International Development.

391 **References**

- 392 1. WHO Guidelines for malaria [Internet]. [cited 2023 Jun 12]. Available from:
393 <https://www.who.int/publications-detail-redirect/guidelines-for-malaria>
- 394 2. World malaria report 2021 [Internet]. [cited 2023 Jun 12]. Available from:
395 <https://www.who.int/publications-detail-redirect/9789240040496>
- 396 3. Shibeshi W, Alemkere G, Mulu A, Engidawork E. Efficacy and safety of artemisinin-based
397 combination therapies for the treatment of uncomplicated malaria in pediatrics: a systematic
398 review and meta-analysis. *BMC Infect Dis.* 2021 Apr 7;21(1):326.
- 399 4. Pluijm RW van der, Imwong M, Chau NH, Hoa NT, Thuy-Nhien NT, Thanh NV, et al. Determinants of
400 dihydroartemisinin-piperaquine treatment failure in *Plasmodium falciparum* malaria in Cambodia,
401 Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. *Lancet Infect*
402 *Dis.* 2019 Sep 1;19(9):952–61.
- 403 5. Gansané A, Moriarty LF, Ménard D, Yerbanga I, Ouedraogo E, Sondo P, et al. Anti-malarial efficacy
404 and resistance monitoring of artemether-lumefantrine and dihydroartemisinin-piperaquine shows
405 inadequate efficacy in children in Burkina Faso, 2017–2018. *Malar J.* 2021 Jan 19;20(1):48.
- 406 6. Moriarty LF, Nkoli PM, Likwela JL, Mulopo PM, Sompwe EM, Rika JM, et al. Therapeutic Efficacy of
407 Artemisinin-Based Combination Therapies in Democratic Republic of the Congo and Investigation
408 of Molecular Markers of Antimalarial Resistance. *Am J Trop Med Hyg.* 2021 Sep 7;tpmd210214.
- 409 7. Ebong C, Sserwanga A, Namuganga JF, Kapisi J, Mpimbaza A, Gonahasa S, et al. Efficacy and safety
410 of artemether-lumefantrine and dihydroartemisinin-piperaquine for the treatment of
411 uncomplicated *Plasmodium falciparum* malaria and prevalence of molecular markers associated
412 with artemisinin and partner drug resistance in Uganda. *Malar J.* 2021 Dec 24;20(1):484.
- 413 8. Malmberg M, Ferreira PE, Tarning J, Ursing J, Ngasala B, Björkman A, et al. *Plasmodium falciparum*
414 Drug Resistance Phenotype as Assessed by Patient Antimalarial Drug Levels and Its Association
415 With *pfmdr1* Polymorphisms. *J Infect Dis.* 2013 Mar 1;207(5):842–7.
- 416 9. Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, et al.
417 Polymorphisms in *Plasmodium falciparum* Chloroquine Resistance Transporter and Multidrug
418 Resistance 1 Genes: Parasite Risk Factors that Affect Treatment Outcomes for *P. falciparum*
419 Malaria after Artemether-Lumefantrine and Artesunate-Amodiaquine. *Am J Trop Med Hyg.* 2014
420 Oct 1;91(4):833–43.
- 421 10. Lim P, Alker AP, Khim N, Shah NK, Incardona S, Doung S, et al. *Pfmdr1* copy number and
422 artemisinin derivatives combination therapy failure in *falciparum* malaria in Cambodia. *Malar J.*
423 2009 Jan 12;8(1):11.
- 424 11. Otienoburu SD, Maïga-Ascofaré O, Schramm B, Jullien V, Jones JJ, Zolia YM, et al. Selection of
425 *Plasmodium falciparum* *pfcr1* and *pfmdr1* polymorphisms after treatment with artesunate–
426 amodiaquine fixed dose combination or artemether–lumefantrine in Liberia. *Malar J.* 2016 Sep
427 5;15(1):452.

- 428 12. Sisowath C, Ferreira PE, Bustamante LY, Dahlström S, Mårtensson A, Björkman A, et al. The role of
429 pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. *Trop Med Int*
430 *Health*. 2007 Jun 1;12(6):736–42.
- 431 13. Happi CT, Gbotosho GO, Folarin OA, Bolaji OM, Sowunmi A, Kyle DE, et al. Association between
432 mutations in Plasmodium falciparum chloroquine resistance transporter and P. falciparum
433 multidrug resistance 1 genes and in vivo amodiaquine resistance in P. falciparum malaria-infected
434 children in Nigeria. *Am J Trop Med Hyg*. 2006 Jul;75(1):155–61.
- 435 14. Baliraine FN, Rosenthal PJ. Prolonged Selection of pfmdr1 Polymorphisms After Treatment of
436 Falciparum Malaria With Artemether-Lumefantrine in Uganda. *J Infect Dis*. 2011 Oct
437 1;204(7):1120–4.
- 438 15. Maiga H, Grivoyannis A, Sagara I, Traore K, Traore OB, Tolo Y, et al. Selection of pfcr1 K76 and
439 pfmdr1 N86 Coding Alleles after Uncomplicated Malaria Treatment by Artemether-Lumefantrine in
440 Mali. *Int J Mol Sci*. 2021 Jan;22(11):6057.
- 441 16. White NJ. How antimalarial drug resistance affects post-treatment prophylaxis. *Malar J*. 2008 Jan
442 11;7(1):9.
- 443 17. Price RN, Uhlemann AC, van Vugt M, Brockman A, Hutagalung R, Nair S, et al. Molecular and
444 Pharmacological Determinants of the Therapeutic Response to Artemether-Lumefantrine in
445 Multidrug-Resistant Plasmodium falciparum Malaria. *Clin Infect Dis*. 2006 Jun 1;42(11):1570–7.
- 446 18. Halsey ES, Venkatesan M, Plucinski MM, Talundzic E, Lucchi NW, Zhou Z, et al. Capacity
447 Development through the US President’s Malaria Initiative–Supported Antimalarial Resistance
448 Monitoring in Africa Network. *Emerg Infect Dis*. 2017 Dec;23(Suppl 1):S53–6.
- 449 19. World Health Organization. Methods for surveillance of antimalarial drug efficacy [Internet]. World
450 Health Organization; 2009 [cited 2022 Mar 22]. Available from:
451 <https://apps.who.int/iris/handle/10665/44048>
- 452 20. Plucinski MM, Morton L, Bushman M, Dimbu PR, Udhayakumar V. Robust Algorithm for Systematic
453 Classification of Malaria Late Treatment Failures as Recrudescence or Reinfection Using
454 Microsatellite Genotyping. *Antimicrob Agents Chemother*. 2015 Sep 18;59(10):6096–100.
- 455 21. Greenhouse B, Myrick A, Dokomajilar C, Woo JM, Carlson EJ, Rosenthal PJ, et al. Validation of
456 microsatellite markers for use in genotyping polyclonal Plasmodium falciparum infections. *Am J*
457 *Trop Med Hyg*. 2006 Nov;75(5):836–42.
- 458 22. Medicines for Malaria Venture, Organization WH. Methods and techniques for clinical trials on
459 antimalarial drug efficacy: genotyping to identify parasite populations: informal consultation
460 organized by the Medicines for Malaria Venture and cosponsored by the World Health
461 Organization, 29-31 May 2007, Amsterdam, The Netherlands [Internet]. World Health
462 Organization; 2008 [cited 2022 Nov 30]. Available from:
463 <https://apps.who.int/iris/handle/10665/43824>

- 464 23. Chebore W, Zhou Z, Westercamp N, Otieno K, Shi YP, Sergeant SB, et al. Assessment of molecular
465 markers of anti-malarial drug resistance among children participating in a therapeutic efficacy
466 study in western Kenya. *Malar J*. 2020 Aug 14;19(1):291.
- 467 24. Sondo P, Derra K, Nakanabo SD, Tarnagda Z, Kazienga A, Zampa O, et al. Artesunate-Amodiaquine
468 and Artemether-Lumefantrine Therapies and Selection of Pfcrt and Pfmdr1 Alleles in Nanoro,
469 Burkina Faso. *PLOS ONE*. 2016 Mar 31;11(3):e0151565.
- 470 25. Conrad MD, LeClair N, Arinaitwe E, Wanzira H, Kakuru A, Bigira V, et al. Comparative impacts over
471 5 years of artemisinin-based combination therapies on *Plasmodium falciparum* polymorphisms
472 that modulate drug sensitivity in Ugandan children. *J Infect Dis*. 2014 Aug 1;210(3):344–53.
- 473 26. Taylor SM, Juliano JJ. Artemisinin Combination Therapies and Malaria Parasite Drug Resistance:
474 The Game Is Afoot. *J Infect Dis*. 2014 Aug 1;210(3):335–7.
- 475 27. Dettori JR, Norvell DC, Chapman JR. Fixed-Effect vs Random-Effects Models for Meta-Analysis: 3
476 Points to Consider. *Glob Spine J*. 2022 Sep;12(7):1624.
- 477 28. Ochong EO, van den Broek IVF, Keus K, Nzila A. Short report: association between chloroquine and
478 amodiaquine resistance and allelic variation in the *Plasmodium falciparum* multiple drug resistance
479 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern
480 Sudan. *Am J Trop Med Hyg*. 2003 Aug;69(2):184–7.
- 481 29. Tinto H, Guekoun L, Zongo I, Guiguemé RT, D’Alessandro U, Ouédraogo JB. Chloroquine-
482 resistance molecular markers (Pfcrt T76 and Pfmdr-1 Y86) and amodiaquine resistance in Burkina
483 Faso. *Trop Med Int Health TM IH*. 2008 Feb;13(2):238–40.
- 484 30. Picot S, Olliaro P, de Monbrison F, Bienvenu AL, Price RN, Ringwald P. A systematic review and
485 meta-analysis of evidence for correlation between molecular markers of parasite resistance and
486 treatment outcome in *falciparum* malaria. *Malar J*. 2009 May 4;8(1):89.
- 487 31. Holmgren G, Gil JP, Ferreira PM, Veiga MI, Obonyo CO, Björkman A. Amodiaquine resistant
488 *Plasmodium falciparum* malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y.
489 *Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis*. 2006 Jul;6(4):309–14.
- 490 32. Djimé AA, Fofana B, Sagara I, Sidibe B, Toure S, Dembele D, et al. Efficacy, Safety, and Selection of
491 Molecular Markers of Drug Resistance by Two ACTs in Mali. *Am J Trop Med Hyg*. 2008 Mar
492 1;78(3):455–61.
- 493 33. Duraisingh MT, Drakeley CJ, Muller O, Bailey R, Snounou G, Targett GA, et al. Evidence for selection
494 for the tyrosine-86 allele of the pfmdr 1 gene of *Plasmodium falciparum* by chloroquine and
495 amodiaquine. *Parasitology*. 1997 Mar;114 (Pt 3):205–11.
- 496 34. Lekana-Douki JB, Dinzouna Boutamba SD, Zatra R, Zang Edou SE, Ekomy H, Bisvigou U, et al.
497 Increased prevalence of the *Plasmodium falciparum* Pfmdr1 86N genotype among field isolates
498 from Franceville, Gabon after replacement of chloroquine by artemether-lumefantrine and
499 artesunate-mefloquine. *Infect Genet Evol J Mol Epidemiol Evol Genet Infect Dis*. 2011
500 Mar;11(2):512–7.

- 501 35. Humphreys GS, Merinopoulos I, Ahmed J, Whitty CJM, Mutabingwa TK, Sutherland CJ, et al.
502 Amodiaquine and Artemether-Lumefantrine Select Distinct Alleles of the Plasmodium falciparum
503 mdr1 Gene in Tanzanian Children Treated for Uncomplicated Malaria. *Antimicrob Agents*
504 *Chemother* [Internet]. 2007 Mar; Available from:
505 <https://journals.asm.org/doi/abs/10.1128/AAC.00875-06>
- 506 36. Sisowath C, Strömberg J, Mårtensson A, Msellem M, Obondo C, Björkman A, et al. In vivo selection
507 of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). *J*
508 *Infect Dis*. 2005 Mar 15;191(6):1014–7.
- 509 37. Dokomajilar C, Nsobya SL, Greenhouse B, Rosenthal PJ, Dorsey G. Selection of Plasmodium
510 falciparum pfmdr1 alleles following therapy with artemether-lumefantrine in an area of Uganda
511 where malaria is highly endemic. *Antimicrob Agents Chemother*. 2006 May;50(5):1893–5.
- 512 38. Somé AF, Séré YY, Dokomajilar C, Zongo I, Rouamba N, Greenhouse B, et al. Selection of Known
513 Plasmodium falciparum Resistance-Mediating Polymorphisms by Artemether-Lumefantrine and
514 Amodiaquine- Sulfadoxine-Pyrimethamine but Not Dihydroartemisinin- Piperazine in Burkina
515 Faso. *Antimicrob Agents Chemother*. 2010 May;54(5):1949–54.
- 516 39. Gadalla NB, Adam I, Elzaki SE, Bashir S, Mukhtar I, Oguike M, et al. Increased pfmdr1 copy number
517 and sequence polymorphisms in Plasmodium falciparum isolates from Sudanese malaria patients
518 treated with artemether-lumefantrine. *Antimicrob Agents Chemother*. 2011 Nov;55(11):5408–11.
- 519 40. Happi CT, Gbotosho GO, Folarin OA, Sowunmi A, Hudson T, O'Neil M, et al. Selection of
520 Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and gametocytes by
521 artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria. *Antimicrob*
522 *Agents Chemother*. 2009 Mar;53(3):888–95.
- 523 41. Baraka V, Tinto H, Valea I, Fitzhenry R, Delgado-Ratto C, Mbonye MK, et al. In vivo selection of
524 Plasmodium falciparum PfCRT and PfMDR1 variants by artemether-lumefantrine and
525 dihydroartemisinin-piperazine in Burkina Faso. *Antimicrob Agents Chemother*. 2015
526 Jan;59(1):734–7.
- 527 42. Zhou Z, Gimnig JE, Sergeant SB, Liu Y, Abong'o B, Otieno K, et al. Temporal trends in molecular
528 markers of drug resistance in Plasmodium falciparum in human blood and profiles of
529 corresponding resistant markers in mosquito oocysts in Asembo, western Kenya. *Malar J*. 2022 Sep
530 13;21(1):265.
- 531 43. Sidhu ABS, Valderramos SG, Fidock DA. pfmdr1 mutations contribute to quinine resistance and
532 enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. *Mol Microbiol*.
533 2005;57(4):913–26.
- 534 44. Veiga MI, Dhingra SK, Henrich PP, Straimer J, Gnädig N, Uhlemann AC, et al. Globally prevalent
535 PfMDR1 mutations modulate Plasmodium falciparum susceptibility to artemisinin-based
536 combination therapies. *Nat Commun*. 2016 May 18;7(1):11553.
- 537 45. Watson OJ, Gao B, Nguyen TD, Tran TNA, Penny MA, Smith DL, et al. Pre-existing partner-drug
538 resistance to artemisinin combination therapies facilitates the emergence and spread of
539 artemisinin resistance: a consensus modelling study. *Lancet Microbe*. 2022 Sep 1;3(9):e701–10.

540 46. Uwimana A, Umulisa N, Venkatesan M, Szigel SS, Zhou Z, Munyaneza T, et al. Association of
541 Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an
542 open-label, single-arm, multicentre, therapeutic efficacy study. *Lancet Infect Dis*. 2021 Aug
543 1;21(8):1120–8.

544 47. Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana SI, Yamauchi M, et al. Evidence of
545 Artemisinin-Resistant Malaria in Africa. *N Engl J Med*. 2021 Sep 23;385(13):1163–71.

546 48. Boni MF, White NJ, Baird JK. The Community As the Patient in Malaria-Endemic Areas: Preempting
547 Drug Resistance with Multiple First-Line Therapies. *PLOS Med*. 2016 Mar 29;13(3):e1001984.

548 49. Peto TJ, Tripura R, Callery JJ, Lek D, Nghia HDT, Nguon C, et al. Triple therapy with artemether-
549 lumefantrine plus amodiaquine versus artemether-lumefantrine alone for artemisinin-resistant,
550 uncomplicated falciparum malaria: an open-label, randomised, multicentre trial. *Lancet Infect Dis*.
551 2022 Jun;22(6):867–78.

552 50. Boni MF. Breaking the cycle of malaria treatment failure. *Front Epidemiol [Internet]*. 2022;2.
553 Available from: <https://www.frontiersin.org/articles/10.3389/fepid.2022.1041896>

554

555

556

557

558

559

560


561

562

563

564

565 **Tables & Figures**



566 **Figure 1.** Countries and sites contributing data to this *Pfmdr1* meta-analysis

Supplementary Table 2. Summary of antimalarial therapeutic efficacy studies, thirteen countries in Africa, 2013–2019

Country	Sites	ACT(s) studied*	Study year(s)	Patient age	Number of samples	Number of patients who completed study	Genotyping method	Publication
Angola	Uige, Zaire	AL, DP	2013	6 mo–9 y	50	320	Microsatellites	(1)
	Benguela, Lunda Sul, Zaire	AL, ASAQ, DP	2015	6 mo–12 y	467	467	Microsatellites	(2,3)
	Benguela, Lunda Sul, Zaire	AL, ASAQ, DP	2017	6 mo–12 y	76	540	Microsatellites	(4)
	Benguela, Lunda Sul, Zaire	AL, ASAQ	2019	6 mo–12 y	106	579	Microsatellites	(5)
Benin	Klouékanmey, Djougou	AL	2017	6 mo–59 mo	175	235	Microsatellites	Country report
DRC	Kabondo, Kapolowe, Kimpese, Mikalayi, Rutshuru	AL, ASAQ, DP	2017–2018	6 mo–59 mo	520	1,271	Microsatellites	(6)
Ethiopia	Arba Minch, Pawe	AL, DP	2017	>6 mo	50	170	Microsatellites	(7)
Guinea	Labé, Maferinyah	AL, ASAQ	2016	6 mo–59 mo	443	413	Microsatellites	(8)
Kenya	Siaya	AL, DP	2016–2017	6 mo–59 mo	415	270	<i>msp1</i> , <i>msp2</i> , <i>glurp</i>	(9, 10)
Madagascar	Ankazomborona, Antensenavolo, Kianjavato, Matanga, Vohitromby	AL, ASAQ	2018	6 mo–14 y	179	335	Microsatellites	(11)
Mali	Sélingué	AL, ASAQ	2015–2016	6 mo–59 mo	386	434	<i>msp1</i> , <i>msp2</i> , <i>glurp</i>	(12)
Mozambique	Massinga, Moatize, Montepuez Mopeia	AL, ASAQ	2018	6 mo–59 mo	158	641	Microsatellites	(13, 14)
Rwanda	Bugarama, Masaka, Rukara	AL	2018	6 mo–59 mo	243	224	Microsatellites	(15)
Tanzania	Kibaha, Mkuzi, Mlimba, Ujiji	AL	2016	6 mo–10 y	339	335	Microsatellites	(16)
Uganda	Aduku, Arua, Masafu	AL, DP	2018–2019	6 mo–10 y	256	590	Microsatellites	(17)
Zambia	Gwembe, Katete, Mansa	AL, ASAQ, DP	2016	>6 mo	266	291	Microsatellites	Country report

*ACTs, artemisinin-based combination therapies; AL, artemether-lumefantrine; ASAQ, artesunate-amodiaquine; DP, dihydroartemisinin-piperaquine; *msp1*, merozoite surface protein-1; *msp2*, merozoite surface protein-2; *glurp*, glutamate-rich protein; DRC, Democratic Republic of the Congo

Table 1. Baseline (pre-treatment) prevalence of *Pfmdr1* single nucleotide polymorphisms*

Marker	Angola	Benin	DRC	Ethiopia	Guinea	Kenya	Madagascar	Mali	Mozambique	Rwanda	Tanzania	Uganda	Zambia	Total
Number of samples	572	164	260	48	420	320	157	311	109	208	271	128	230	3,135
<i>Pfmdr1</i>[†] 86														
Sequenced	511	152	258	48	385	320	153	255	109	208	269	128	203	2,999
N	433 (85)	144 (89)	138 (53)	47 (99)	306 (80)	319 (99)	120 (78)	206 (81)	109 (100)	200 (95)	268 (99)	128 (100)	202 (99)	2,620 (87)
N/Y	8 (2)	1 (<1)	38 (15)	0	24 (6)	1 (<1)	4 (3)	15 (6)	0	5 (4)	0	0	0	96 (3)
Y	70 (13)	17 (10)	82 (32)	1 (<1)	55 (14)	0	29 (19)	34 (13)	0	3 (<1)	1 (<1)	0	1 (<1)	293 (10)
<i>Pfmdr1</i> 184														
Sequenced	512	162	258	48	385	320	154	293	109	208	270	128	203	3,050
Y	341 (66)	43 (27)	150 (58)	11 (23)	119 (31)	130 (41)	53 (34)	83 (28)	42 (39)	99 (47)	165 (61)	48 (37)	127 (63)	1,411 (46)
Y/F	39 (8)	27 (17)	60 (23)	2 (4)	56 (14)	77 (24)	9 (6)	34 (12)	24 (22)	20 (10)	0	37 (29)	4 (2)	389 (14)
F	132 (26)	92 (56)	48 (19)	35 (73)	210 (55)	113 (35)	92 (60)	176 (60)	43 (39)	89 (43)	105 (39)	43 (34)	72 (35)	1,250 (40)
<i>Pfmdr1</i> 1034														
Sequenced	503	150	260	47	374	320	149	307	109	207	270	126	184	3,006
S	503 (100)	150 (100)	258 (99)	47 (100)	374 (100)	320 (100)	149 (100)	307 (100)	109 (100)	207 (100)	270 (100)	126 (100)	184 (100)	3,004 (99)
S/C	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C	0	0	2 (<1)	0	0	0	0	0	0	0	0	0	0	2 (<1)
<i>Pfmdr1</i> 1042														
Sequenced	503	150	260	48	374	320	149	307	109	206	270	127	183	3,006
N	503 (100)	150 (100)	258 (99)	48 (100)	374 (100)	320 (100)	149 (100)	307 (100)	109 (100)	206 (100)	270 (100)	127 (100)	183 (100)	3,004 (99)
N/D	0	0	0	0	0	0	0	0	0	0	0	0	0	0
D	0	0	2 (<1)	0	0	0	0	0	0	0	0	0	0	2 (<1)
<i>Pfmdr1</i> 1246														
Sequenced	513	150	260	48	371	320	139	307	109	208	270	127	205	3,027
D	505 (98)	150 (100)	210 (81)	48 (100)	362 (97)	289 (89)	133 (96)	302 (98)	10 (100)	194 (93)	268 (99)	116 (91)	201 (98)	2,887 (95)
D/Y	0	0	18 (7)	0	3 (1)	(20 (7)	0	0	0	4 (2)	0	5 (4)	2 (1)	52 (2)
Y	8 (2)	0	32 (12)	0	6 (2)	11 (4)	6 (4)	5 (2)	0	10 (5)	2 (1)	6 (5)	2 (1)	88 (3)

*Values are no. (%) of successfully sequenced samples

[†]*Pfmdr1*=*Plasmodium falciparum multidrug resistance 1* gene.

Table 2. Selection of *Pfmdr1* genotypes after treatment with artemether-lumefantrine, artesunate-amodiaquine, and dihydroartemisinin-piperaquine*

Marker	Genotype [†]	Recurrent infection			Recrudescence infection			New infection		
		AL	ASAQ	DP	AL	ASAQ	DP	AL	ASAQ	DP
<i>Pfmdr1</i> 86	N→Y	(11/647)	(9/99)	(22/205)	(1/153)	(1/27)	(2/37)	(10/494)	(8/72)	(20/168)
□	Y→N	(32/647)	(22/99)	(26/205)	(3/153)	(5/27)	(3/37)	(29/494)	(17/72)	(23/168)
□	No change**	(604/647)	(68/99)	(157/205)	(149/153)	(21/27)	(32/37)	(455/494)	(47/72)	(125/168)
P value	□	<0.01	0.03 (exact)	0.56	0.62	0.22 (exact)	1 (exact)	<0.01	0.11 (exact)	0.65
<i>Pfmdr1</i> 184	Y→F	(119/639)	(17/101)	(44/205)	(22/153)	(15/36)	(7/37)	(95/486)	(10/74)	(39/168)
□	F→Y	(117/639)	(16/101)	(35/205)	(27/153)	(2/36)	(5/37)	(92/486)	(15/74)	(28/168)
□	No change**	(403/639)	(68/101)	(126/205)	(104/153)	(19/36)	(25/37)	(299/486)	(49/74)	(101/168)
P value	□	0.89	1	0.31	0.48	0.29 (exact)	0.77 (exact)	0.82	0.42 (exact)	0.18
<i>Pfmdr1</i> 1246	D→Y	(9/618)	(6/105)	(16/205)	(2/150)	(2/27)	(2/37)	(7/468)	(6/78)	(14/168)
□	Y→D	(17/618)	(8/105)	(9/205)	(2/150)	(2/27)	(2/37)	(15/468)	(4/78)	(7/168)
□	No change**	(592/618)	(91/105)	(180/205)	(146/150)	(23/27)	(33/37)	(446/468)	(68/78)	(147/168)
P value	□	0.17	0.77 (exact)	0.16	1	1 (exact)	1 (exact)	0.14	0.75 (exact)	0.19

AL, artemether-lumefantrine; ASAQ, artesunate-amodiaquine; DP, dihydroartemisinin-piperaquine

*Values in bold indicate statistically significant selection (P<0.05) using McNemar's paired test. Those marked exact were tested by using the exact distribution for sample sizes less than 100.

Pfmdr1=*Plasmodium falciparum multidrug resistance 1* gene

†Each category includes all changes from one allele to another. For example, N→Y includes N→Y, N→N/Y, and N/Y→Y changes; Y→N includes Y→N, Y→N/Y, N/Y→N changes.

**No change in genotype from before and after treatment.

Note: recurrent infections are the combination of recrudescence and new infections




Figure 2. a) Forest plot of recurrent parasitemia in patients treated with AL. Odds ratio of N86 among patients with recurrent parasitemia compared to the odds ratio of N86 among patients who successfully cleared the infection. b) Forest plot of recurrent parasitemia in patients treated with ASAQ. Odds ratio of 86Y among patients with recurrent parasitemia compared to the odds ratio of 86Y among those who successfully cleared the infection. c) Forest plot of recurrent parasitemia in patients treated with DP. Odds ratio of 86Y among patients with recurrent parasitemia compared to the odds ratio of 86Y among patients who successfully cleared the infection. AL, artemether-lumefantrine; ASAQ, artesunate-amodiaquine; DP, dihydroartemisinin-piperazine; OR, odds ratio; CI, confidence interval.




Figure 3. a) Forest plot of recurrent parasitemia in patients treated with AL. Odds ratio of 184F among patients with recurrent parasitemia compared to the odds ratio of 184F among patients who successfully cleared the infection. b) Forest plot of recurrent parasitemia in patients treated with ASAQ. Odds ratio of Y184 among patients with recurrent parasitemia compared to the odds ratio of Y184 among patients who successfully cleared the infection. c) Forest plot of recurrent parasitemia in patients treated with DP. Odds ratio of 86Y among patients with recurrent parasitemia compared to the odds ratio of Y184 among patients who successfully cleared the infection. AL, artemether-lumefantrine; ASAQ, artesunate-amodiaquine; DP, dihydroartemisinin-piperaquine; OR, odds ratio; CI, confidence interval.




Figure 4. **a)** Forest plot of recurrent parasitemia in patients treated with AL. Odds ratio of D1246 among patients with recurrent parasitemia compared to the odds ratio of D1246 among patients who successfully cleared the infection. **b)** Forest plot of recurrent parasitemia in patients treated with ASAQ. Odds ratio of 1246Y among patient with recurrent parasitemia compared to the odds ratio of 1246Y among patients who successfully cleared the infection. **c)** Forest plot of recurrent parasitemia in patients treated with DP. Odds ratio of 1246Y among patients with recurrent parasitemia compared to the odds ratio of 1246Y among patients who successfully cleared the infection. AL, artemether-lumefantrine; ASAQ, artesunate-amodiaquine; DP, dihydroartemisinin-piperazine; OR, odds ratio; CI, confidence interval.

Supplementary Table 1. Uncorrected and PCR-corrected efficacies for therapeutic efficacy study sites

Country	Site	Year(s) of study	AL uncorrected efficacy (% 95% CI)	AL PCR-corrected efficacy (% 95% CI)	ASAQ uncorrected efficacy (% 95% CI)	ASAQ PCR-corrected efficacy (% 95% CI)	DP uncorrected efficacy (% 95% CI)	DP PCR-corrected efficacy (% 95% CI)
Angola	Uige	2013	92 [84–97]	97 [91–100]	–	–	100 ^a	100 ^a
	Zaire		77 [69–87]	88 [79–95]*	–	–	99 [96–100]	100 ^a
	Benguela	2015	90 [83–96]	96 [89–99]	90 [84–97]	99 [95–100]	–	–
	Lunda Sul		–	–	100	100	100	100
	Zaire		76 [68–85]	88 [81–95]*	–	–	96 [91–100]	99 [96–100]
	Benguela	2017	–	–	99 [97–100]	100 [97–100]	100 [100–100]	100
	Lunda Sul		90 [82–95]	96 [90–99]	–	–	101 [100–100]	101 [100–100]
	Zaire		93 [88–98]	96 [91–100]	82 [75–90]	93 [88–99]	–	–
	Benguela	2019	90 [85–96]	98 [96–100]	100 ^a	100 ^a	–	–
	Lunda Sul		85 [79–93]	88 [81–95]*	100 ^a	100 ^a	–	–
Zaire	84 [77–92]		92 [87–98]	85 [78–92]	96 [91–100]	–	–	
Benin	Klouékanmey	2017	99 [94–100]	100 [97–100]	–	–	–	–
	Djougou		91 [83–98]	98 [94–100]	–	–	–	–
	Kabondo		88 [82–95]	98 [95–100]	100 [100–100]	100 [100–100]	91 [85–98]	100 [99–100]
DRC	Kapolowe	2017–2018	76 [68–85]	94 [89–99]	100 [100–100]	100 [100–100]	64 [56–75]	93 [87–99]
	Kimpese		85 [78–94]	96 [92–100]	93 [88, 99]	99 [98–100]	90 [84–97]	100 [99–100]
	Mikalayi		63 [55–74]	86 [79, 93]*	77 [69–86]	96 [91–99]	56 [47–67]	84 [75–93]*
	Rutshuru		80 [72–89]	96 [92–100]	73 [64–83]	91 [85–98]	59 [50–70]	95 [90–100]
Ethiopia	Arbaminch	2017	100 ^a	100 ^a	–	–	100 ^a	100 ^a
	Pawe		98 [91–99]	98 [91–99]	–	–	100 ^a	100 ^a
Guinea	Labé	2016	94 [90–99]	99 [97–100]	97 [94–100]	99 [97–100]	–	–
	Maferinyah		92 [87–98]	100 ^a	95 [91–99]	100 ^a	–	–
Kenya	Siaya	2016–2017	68 [61–76]	91 [86–96]	–	–	77 [70–84]	94 [89–98]

Madagascar	Ankazomborona	2018	99 [97–100]	100 [99–100]	100 [100–100]	100 [100–100]	–	–
	Matanga		83 [76–92]	95 [91–100]	95 [91–100]	98 [95–100]	–	–
Mali	Sélingué	2015–2016	84 [79–89]	92 [88–97]	93 [90–97]	97 [95–99]	–	–
Mozambique	Massinga	2018	73 [62–82]	95 [87–99]	99 [94–100]	100 [96–100]	–	–
	Moatize		98 [91–100]	100 [95–100]	–	–	–	–
	Montepuez		96 [90–99]	100 [96–100]	100 [96–100]	100 [96–100]	–	–
	Mopeia		76 [66–85]	96 [88–99]	98 [92–100]	99 [94–100]	–	–
Rwanda	Bugarama	2018	84 [75–91]	97 [91–100]	–	–	–	–
	Masaka		96 [86–100]	97 [88–100]	–	–	–	–
	Rukara		76 [65–84]	94 [85–98]	–	–	–	–
Tanzania	Kibaha	2018	86 [76–92]	99 [93–100]	–	–	–	–
	Mkuzi		65 [54–75]	97 [88–100]	–	–	–	–
	Mlimba		86 [77–93]	100 [94–100]	–	–	–	–
	Ujiji		74 [63–83]	99 [92–100]	–	–	–	–
Uganda	Kwania	2018–2019	71 [61–80]	94 [90–99]	–	–	87 [81–94]	98 [95–100]
	Arua		61 [50–70]	92 [86–98]	–	–	79 [71–88]	94 [90–99]
	Busia		41 [32–51]	87 [67–90]*	–	–	74 [65–83]	92 [87–98]
Zambia [†]	Gwembe Katete Mansa	2016	86 [77–93]	100 [95–100]	98 [92–100]	100 [96–100]	87 [78–93]	100 [95–100]

*PCR-corrected efficacy less than WHO suggested 90% threshold

Hyphens indicate a drug was not used in the study


a=Confidence intervals are undefined

[†]Uncorrected and PCR-corrected efficacies were calculated from Gwembe, Katete, and Mansa samples pooled together
 AL, artemether-lumefantrine; ASAQ, artesunate-amodiaquine; DP, dihydroartemisinin-piperaquine; CI, confidence interval.

Studies using AL, codon 86 (n=1,033; 54 recrudescences)


Angola, 2015
 Benin, 2017
 Democratic Republic of the Congo, 2018
 Guinea, 2016
 Madagascar, 2018
 Mali, 2017
 Rwanda, 2018
 Tanzania, 2016

Common effect model




Supplementary Figure 1. Forest plot of recrudescence in patients treated with AL. Odds ratio of N86 among patients with recrudescence compared to the odds ratio of N86 among patients who successfully cleared the infection. OR, odds ratio; CI, confidence interval.

a)



b)



Supplementary Figure 2. a) Forest plot of recrudescence in patients treated with AL. Odds ratio of 184F among patients with recrudescence compared to the odds ratio of 184F among patients who successfully cleared the infection. **b)** Forest plot of recrudescence in patients treated with

ASAQ. Odds ratio of Y184 among patients with recrudescence compared to the odds ratio of Y184 among patients who successfully cleared the infection. OR, odds ratio; CI, confidence interval.